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 2010 EMBO Molecular MedicineThe protein kinase Aurora-A is a major regulator of the cell cycle that orchestrates
mitotic entry and is required for the assembly of a functional mitotic spindle.
Overexpression of Aurora-A has been strongly linked with oncogenesis and this
has led to considerable efforts at therapeutic targeting of the kinase activity of
this protein. However, the exact mechanism by which Aurora-A promotes onco-
genesis remains unclear. Here, we show that Aurora-A modulates the repair of
DNA double-strand breaks (DSBs). Aurora-A expression inhibits RAD51 recruit-
ment to DNA DSBs, decreases DSB repair by homologous recombination and
sensitizes cancer cells to PARP inhibition. This impairment of RAD51 function
requires inhibition of CHK1 by Polo-like kinase 1 (PLK1). These results identify a
novel function of Aurora-A in modulating the response to DNA DSB that likely
contributes to carcinogenesis and suggest a novel therapeutic approach to the
treatment of cancers overexpressing this protein.INTRODUCTION
Aurora-A is a centrosome-associated, cell cycle-regulated
member of the Aurora serine/threonine protein kinase family
which is important for mitosis (Bischoff & Plowman, 1999;
Carmena & Earnshaw, 2003; Giet & Prigent, 1999; Nigg, 2001).
The protein level and activity of Aurora-A peaks at G2 and
during mitosis whereas expression is low in resting cells (Sasai
et al, 2008; Zhou et al, 1998). A variety of Aurora-A substrates
have been identified, of which the best characterized are p53,
TPX2, Ajuba and D-TACC (Hirota et al, 2003; Meraldi et al,
2004). Aurora-A is essential for multiple processes during
mitosis, including mitotic spindle formation and activation of
cell cycle regulators such as PLK1 and CDK1 (Cazales et al, 2005;
Seki et al, 2008). Perhaps unsurprisingly, targeting Aurora-Ae Institute of Cancer
ics, The Institute of
icr.ac.ukpharmacologically, by RNA interference or by genetic knockout,
leads to aberrant mitosis and cell death (Manfredi et al, 2007;
Sasai et al, 2008). The Aurora-A gene is located on human
chromosome 20q13—a region that is amplified in a variety of
human tumours (Kallioniemi et al, 1994). Aurora-A is over-
expressed in a broad range of human tumours, including
primary colorectal carcinoma, gliomas and breast, ovarian and
pancreatic cancers (Bischoff et al, 1998; Gritsko et al, 2003; Zhou
et al, 1998). Ectopic expression of Aurora-A induces, under
certain conditions, abnormal spindle formation leading to
polyploidy and has been reported to transformNIH3T3 and Rat1
fibroblasts (Bischoff et al, 1998; Meraldi et al, 2002; Zhou et al,
1998). Nevertheless, the exact mechanisms by which Aurora-A
overexpression induces tumorigenicity remain unclear. A role of
Aurora-A not directly linked to mitosis is its involvement in
DNA-damage response (DDR). Aurora-A activity is tightly
regulated during the response to genotoxic agents and is
important for a normal DDR (Cazales et al, 2005; Krystyniak
et al, 2006).
DNA damage is continuously generated by a variety of
mechanisms including cell metabolism, exogenous genotoxic
agents and the collapse of replication forks. Amongst the manyEMBO Mol Med 2, 130–142 www.embomolmed.org
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especially lethal if left unrepaired. Deficiency in the DNA repair
processes that normally deal with DSBs is associated with
cancer susceptibility as illustrated by the tumour suppressor
activity of breast and ovarian cancer susceptibility genes BRCA1
and BRCA2 which both are part of the DSB repair machinery
(Kastan & Bartek, 2004). There are two mechanistically distinct
pathways repairing DSBs, the non-homologous end-joining
(NHEJ) and the homologous recombination (HR) pathways. The
NHEJ pathway mediates the re-ligation of the two broken DNA
ends, while HR involves the use of a homologous sequence as a
template to faithfully repair the damaged region. Consequently
HR is an essentially error-free repair pathway whereas NHEJ is
mostly error-prone and generates mutations. HR requires a
readily available homologous DNA sequence, a condition that is
best fulfilled once the DNA has been replicated, in the S and G2
phases of the cell cycle. Indeed, HR is repressed in G1, and
becomes activated during S and G2 phases, while NHEJ is
constitutively active throughout the cell cycle (Mao et al,
2008b).
There is an intricate connection between the DDR and the cell
cycle at multiple levels. First, as a response to a DSB is elicited,
selection of the most appropriate DSB repair pathway occurs.
This crucial step, which may have dramatic consequences on
themaintenance of genome integrity, is considerably affected by
cell cycle phase. Recent findings have illuminated the mechan-
istic basis for the cell cycle-dependent activation of DNA repair
pathways. In both yeast and mammals, the G2 cyclin-dependent
kinase CDK1 stimulates 50–30 resection of the DSB ends (Jazayeri
et al, 2006). This modification is specifically required for HR,
generates a substrate for the initiation of this process, and also
triggers the full activation of the DNA damage checkpoint
(Aylon et al, 2004; Huertas et al, 2008; Huertas & Jackson, 2009;
Ira et al, 2004; Jazayeri et al, 2006). At a subsequent stage, once
the HRmachinery is fully active, the cell cycle is normally stalled
by the activation of the DNA damage checkpoints. For the G2/M
DNA damage checkpoint, the cell cycle arrest is mostly
contributed by the regulation of CDC25 phosphatases and
WEE1 either by the checkpoint kinases CHK1 and CHK2 or by
the ATM/ATR kinases-dependent phosphorylation of PLK1.
These two pathways converge tomaintain an efficient inhibition
of CDK1 and hence prevent cell cycle progression. Finally,
during the DNA damage checkpoint recovery, the signal
emanating from the mitotic kinase PLK1 becomes dominant
and stimulates cell cycle progression. Interestingly, during this
late phase of the DDR, but also during unperturbed cell cycle,
Aurora-A has been identified as the upstream activator of PLK1
(Macurek et al, 2008; Seki et al, 2008). The resulting activation
of CDK1 stems from two complementary, concomitant actions.
Firstly, PLK1 and Aurora-A directly regulate CDC25 and WEE1.
Secondly, PLK1 activation, by mediating a phosphorylation
dependent degradation of Claspin, leads to the inactivation of
CHK1 and hence alleviates the opposing effect of the checkpoint
protein to the cell cycle (Mamely et al, 2006; Peschiaroli et al,
2006). In addition, the core machinery of HR is also targeted by
the checkpoint recovery signalling. BRCA2 activity, which is
required for RAD51 loading onto single-strand DNA (ssDNA), iswww.embomolmed.org EMBO Mol Med 2, 130–142also controlled by PLK1- and CDK-triggered phosphorylation
(Esashi et al, 2005; Lee et al, 2004).
It appears, therefore, that a proper balance between the
activity of cell cycle regulators and DNA repair proteins is
crucial to produce an adapted response to DNA damage. One of
the major regulators of the cell cycle, Aurora-A, is aberrantly
expressed in cancer and its deregulation is a driving event in
tumour formation (Greenman et al, 2007). This led us to
investigate if the misexpression of Aurora-A observed in cancer
could affect the DDR. We found that expression of high Aurora-
A levels leads to the silencing of HR, the major error-free DSB
repair pathway, in response to DNA damage. Aurora-A
overexpression represses CHK1 kinase activity and the repres-
sion of HR requires the activation of PLK1. We propose that this
function of Aurora-A could contribute to the oncogenic activity
of Aurora-A and provide basis for novel therapeutic strategies.RESULTS AND DISCUSSION
Aurora-A overexpression impairs RAD51 focus formation
To assess the potential effect of Aurora-A on HR, we examined
the formation of nuclear RAD51 foci after DNA damage. The
localization of these foci after damage most likely represents the
loading of the RAD51 DNA recombinase onto damaged DNA, an
essential part of the HR process known to be controlled by other
HR proteins, such as BRCA1 and BRCA2 (West, 2003). MCF10A
cells were infected with lentiviral vectors expressing either high
levels of both Aurora-A and GFP (from a bicistronic mRNA) or
GFP alone. The levels of overexpressed Aurora-A in the infected
MCF10A cell lines were comparable to the levels of Aurora-A
found in a panel of cancer cell lines (Supporting Information
Fig 1). In MCF10A cells expressing high levels of Aurora-A,
RAD51 focus induction was impaired, suggesting a potentially
repressive effect of Aurora-A on HR (Fig 1A, B). To address
whether high Aurora-A levels altered the sensing of DNA
lesions, we also examined the formation of serine 139
phosphorylated histone H2AX (g-H2AX) nuclear foci (Bonner
et al, 2008). High level Aurora-A expression did not affect
g-H2AX foci formation, suggesting that DNA damage sensing
was not altered (Fig 1A, C). To exclude the possibility that these
effects were specific to the cell model used, we also assessed
RAD51 and g-H2AX foci formation in mouse embryonic stem
(ES) cells (Supporting Information Fig 2). ES cells transfected
with a plasmid driving the expression of a myc-tagged Aurora-A
showed impaired RAD51 foci formation upon X-ray treatment,
while eliciting a normal g-H2AX foci induction. As a control, ES
cells lacking a functional HR pathway due to BRCA2 gene
inactivation were used. A reduction of RAD51 foci formation
was also observed (Farmer et al, 2005); (BRCA2–/–; Supporting
Information Fig 2A).
Given that Aurora-A is a kinase, we assessed whether
catalytic activity was required for the modulation of RAD51
function. Pre-treatment of MCF10A cells overexpressing Aurora-
A with a specific Aurora-A kinase inhibitor MLN8054,
at concentrations that preferentially inhibit Aurora-A (Manfredi
et al, 2007), restored normal RAD51 foci induction in response 2010 EMBO Molecular Medicine 131
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Figure 1. Impairment of irradiation-induced RAD51 nuclear focus formation by Aurora-A overexpression. MCF10A cells were infected with a lentivirus
construct driving the expression of GFP (empty vector) or both GFP and Aurora-A (Aurora-A) and mixed in equal proportion with non-infected cells to provide an
internal control. The mixed cells were exposed to 5-Gy X-ray, followed by a 24 h (A) or 4, 16 or 32 h (B and C) recovery.
A. Immunofluorescence images of MCF10A cells stained for RAD51 (grey) and g-H2AX (red). Green fluorescence indicates GFP expression by infected cells. DNA
was counterstained with DAPI (blue). Arrowheads indicate empty vector infected or Aurora-A overexpressing cells.
B, C. Quantification of RAD51 (B) and g-H2AX (C) foci-positive nuclei. Immunofluorescence images of MCF10A were acquired as in (A). The cells were pre-treated
with the Aurora-A inhibitor MLN8054 (Aurora-AþMLN8054) or vehicle, 1 h before irradiation. Nuclei containing more than three foci were scored as
positive. The percentage of RAD51 (B) or g-H2AX (C) positive nuclei of non-infected (GFP negative) or infected (GFP positive) cells was plotted. Error bars
represent SEM. Results are representative of at least two independent experiments.
132to ionizing radiation (Fig 1B). The specificity of this effect was
confirmed by the observation that the Aurora-B kinase inhibitor
ZM447439 (Ditchfield et al, 2003) was unable to restore the
RAD51 response in cells expressing high levels of Aurora-A
(Supporting Information Fig 3). The requirement of Aurora-A
kinase activity for the inhibition of RAD51 foci formation was
also confirmed by the use of a kinase inactive mutant of Aurora-
A (Aurora-A D256A; Jiang et al, 2003; Supporting Information
Fig 4).
The effect of Aurora-A on HR is not caused by cell cycle
perturbation
The cellular choice between NHEJ and HR is regulated during
the cell cycle and therefore, reduced activity of the HR pathways
could conceivably result from modulation of the cell cycle by
Aurora-A overexpression. To exclude this possibility, we
monitored the cell cycle profile of irradiated MCF10A and ES
cells by flow cytometry (Fig 2; Supporting Information Fig 2C).
In these experimental systems, we did not observe the gene-
ration of polyploid cells upon overexpression of Aurora-A as
described in other experimental settings (Meraldi et al, 2002;
Supporting Information Fig 5). As expected, irradiation resulted
in a cell cycle arrest in both cellular models. DNA profiles of
MCF10Awere performed at various times after irradiation. Up to
16 h after irradiation, the DNA profiles of Aurora-A over-
expressing and normal cells were indistinguishable. As, at this 2010 EMBO Molecular Medicinetime, a pronounced effect of Aurora-A overexpression on RAD51
foci formation is already clearly visible, we conclude that
Aurora-A kinase activity modulates the HR independently of its
function in cell cycle. However, at later time points, the presence
of high levels of Aurora-A leads to cell cycle re-entry. Therefore,
it is possible that, as the DNA damage checkpoint weakens, the
kinase may overcome the arrest. Alternatively, this might reflect
that a faster and therefore, less accurate repair pathway, such as
NHEJ, operates in these conditions.
Aurora-A overexpression inhibits HR
As RAD51 activity is essential for HR, we assessed whether the
impairment of RAD51 foci formation by Aurora-A overexpres-
sion could lead to a corresponding silencing of homology
directed DNA repair itself. To address this, we used a previously
validated synthetic DSB repair substrate stably introduced into
293 cells. This model is based on the induction of a DSB by the
restriction enzyme I-SceI at a single chromosomal locus. When
this lesion is repaired by a homology-directed mechanism, a
functional blasticidin resistance gene is generated (Tutt et al,
2001; Fig 3A). Using either colony formation (Fig 3B, C) or GFP
competition (Fig 3D, E) assays to estimate blasticidin resistance,
fewer blasticidin resistant 293 cells were generated when
Aurora-A was overexpressed, suggesting that HR is repressed by
Aurora-A in this model. In line with the RAD51 foci formation
assay, the kinase activity of Aurora-A is required for its effect onEMBO Mol Med 2, 130–142 www.embomolmed.org
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Figure 2. Effect of Aurora-A overexpression on the DNA damage-induced cell cycle arrest.
A. MCF10A cells were infected with a lentivirus construct driving the expression of GFP (empty vector) or both GFP and Aurora-A (Aurora-A) and mixed in equal
proportion with non-infected cells to provide an internal control (fluorescence images, top left panel). The mixed cells were exposed to 5-Gy X-ray, followed by
a 16, 24 or 40 h recovery, or left untreated, as indicated. The DNA was counterstained by Hoechst 33342, and the DNA profiles of infected (GFP positive) and
uninfected (GFP negative cells) were acquired separately by flow cytometry.
B. The percentage of cells in each phase of the cell cycle was determined from the DNA profiles shown in (A) and plotted.HR, as the overexpression of a kinase inactive mutant, Aurora-A
S361, did not affect the acquisition of blasticidin resistance
in this assay (Fig 3B-E; Bibby et al, 2009). We also verified
that the cell cycle profile of the 293 cells was unperturbed by
Aurora-A overexpression in these experiments (Supporting
Information Fig 6). Taken together, these results indicate
that Aurora-A exerts a repressive effect on the DNA repair
by HR.
Aurora-A regulates HR through the PLK1/CHK1 pathway
The presence of DNA damage triggers a coordinated cellular
response aimed at repairing damaged DNA while at the same
time stalling the cell cycle so that damage is not eventuallywww.embomolmed.org EMBO Mol Med 2, 130–142passed onto daughter cells. Unsurprisingly, cross-talk between
repair and checkpoint pathways has been described (Harper &
Elledge, 2007). Interestingly, the Polo-like kinase (PLK1) was
recently shown to control the degradation of Claspin (Mamely et
al, 2006) and hence the activity of the checkpoint protein CHK1,
which is also required for HR (Sorensen et al, 2005). Aurora-A
kinase has been identified as an upstream activator of PLK1
(Seki et al, 2008). Based on these observations we investigated
whether high level Aurora-A expression could modulate HR
activity through a PLK1-mediated regulation of the CHK1-
Claspin complex.
We first determined the activity of PLK1 in either irradiated
(5Gy) or untreated MCF10A cells expressing endogenous or 2010 EMBO Molecular Medicine 133
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Figure 3. HR deficiency in Aurora-A overexpressing
cells.
A. Schematic representation of the HR repair
substrate DR1Bsd. The single copy HR reporter
construct chromosomally integrated into HEK
293 cells consists of two tandem copies of the
blasticidin resistance gene (Bsd). The insertion of
an I-SceI restriction site (black vertical dashes),
which also encodes two in-frame stop codons,
into the upstream copy of the blasticidin-resist-
ance gene (S1Bsd; grey box) prevents its
expression. The downstream copy of the gene
(50DBsd; black diagonal dashed box) is
promoterless, and hence non-functional.
Expression of the I-SceI restriction enzyme
induces a DNA DSB at the I-SceI restriction site in
S1Bsd. The repair of this lesion by NHEJ will
mostly leave the S1Bsd gene non-functional,
whereas HR mechanisms, using the 50DBsd copy
as a repair template, generates a functional gene
and cell resistance to blasticidin.
B. 293 cells bearing the HR repair substrate DR1Bsd
were infected with a lentiviral vector expressing
GFP alone (empty vector), or GFP along with
Aurora-A (Aurora-A) or a kinase inactive Aurora-A
mutant (Aurora-A S361). Infection efficiency was
monitored in flow cytometry by the measure-
ment of GFP expression (infection efficiency).
Non-infected cells were included as a control. The
plasmid encoding the NLS-tagged I-SceI restric-
tion enzyme was co-transfected with a DsRed
expressing construct. The transfection efficiency
was assessed by flow cytometry measurement of
DsRed expression (transfection efficiency).
Cells were then grown in normal medium (no
selection) or in the presence of blasticidin
(blasticidin) and stained with crystal violet as
described in material and methods.
C. Colonies formed in the presence of blasticidin
were scored and plotted, after normalization by
the platting efficiency (number of colonies
formed in the absence of blasticidin) and
the transfection efficiency. Results are
representative of at least two independent
experiments. Error bars represent SEM.
D. 293 cells bearing the HR repair substrate DR1Bsd
were infected with a lentivirus construct driving
the expression of GFP (empty vector), GFP along
with Aurora-A (Aurora-A), a kinase inactive
Aurora-A mutant (Aurora-A S361) or Gadd45a
(Gadd45a) and mixed with non-infected cells to
provide an internal control. The mixed cells were
co-transfected with NLS-tagged I-SceI and DsRed
expression plasmids. Transfection efficiency was
assessed by flow cytometry measurement of
DsRed expression (transfection efficiency). The
GFP expression was analysed by flow cytometry
in cells maintained in normal (no selection), or
blasticidin-containing (blasticidin) medium.
. Ratio of GFP-positive cells after blasticidin
selection versus non-selected cells as measured
in (D). The average of two independent
experiments is shown. Error bars represent SEM.
134high levels of Aurora-A (Fig 4A). Using an antibody specific
to the active threonine 210 phosphorylated form of PLK1
(p-Thr210-PLK1), we observed an increased PLK1 activity in
cells expressing high Aurora-A levels. Moreover, the Aurora-A-
mediated activation of PLK1 kinase activity was not affected by
irradiation. We next tested the requirement of PLK1 activation
for Aurora-A impairment of RAD51 focus formation by using a
specific inhibitor of PLK1 kinase activity, BI2536 (Steegmaier et
al, 2007). Inhibition of PLK1 efficiently abolished the effect of
Aurora-A on RAD51 foci induction (Fig 4B), indicating that PLK1
activation is required for the impairment of RAD51 foci
induction by Aurora-A.
To address whether the constitutive activation of PLK1 by
Aurora-A could affect CHK1 activity, we immunoprecipitated 2010 EMBO Molecular Medicine EMBO Mol Med 2, 130–E142 www.embomolmed.org
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Figure 4. Aurora-A activation of PLK1 is required for the impairment of RAD51
focus formation.
A. Immunoblot analysis of total PLK1, threonine 210 phosphorylated
PLK1 (p-T210-PLK1) and Aurora-A in non-irradiated or irradiated (5 Gy)
MCF10A cells infected with a lentiviral construct expressing GFP alone
(empty vector) or GFP and Aurora-A (Aurora-A). Ezrin was used as loading
control.
B. PLK1 activity is required for the inhibition of RAD51 nuclear focus
formation by Aurora-A. MCF10A cells were infected with a lentivirus
construct driving the expression of GFP (empty vector) or both GFP and
Aurora-A (Aurora-A) and mixed in equal proportion with non-infected cells
to provide an internal control. The mixed cells were pre-treated with the
PLK1 kinase inhibitor BI2536 (þBI2536) or with vehicle (–BI2536), 1 h
before a 5-Gy X-ray treatment, followed by a 4, 16, 24 or 30 h recovery, as
indicated. RAD51 foci were then detected by immunofluorescence and
RAD51 foci-positive nuclei were scored in uninfected (GFP negative) and
infected (GFP positive) cells as described in Fig 1B. Shown is the average
percentage of RAD51 foci positive cells from two independent
experiments. Error bars indicate SEM.CHK1 from MCF10A cells with varying levels of Aurora-A
expression, and assessed the ability of CHK1 to phosphorylate
the substrate myelin binding protein (MBP) in vitro. Both, basal
and DNA-damage-induced CHK1 activities were decreased inwww.embomolmed.org EMBO Mol Med 2, 130–142MCF10A cells overexpressing Aurora-A (Fig 5A, B). Similar
samples were analysed by immunoblot in order to directly
monitor the phosphorylation status of CHK1. Two major
activating phosphorylations of CHK1, on serine 317 and serine
345 (p-Ser317-CHK1 and p-Ser345-CHK1, respectively) were
decreased in cells expressing high levels of Aurora-A (Fig 5C).
The effect of Aurora-A was most likely specific to CHK1, as the
activity of CHK2, when monitored by its autophosphorylation
on the threonine 68 (p-T68-CHK2) residue, was not affected
(Fig 5C). Finally, both basal and radiation-induced Claspin
levels were also decreased by the presence of high Aurora-A
levels (Fig 5C). Taken together, these results suggest that
Aurora-A modulates CHK1 activity through PLK1-triggered
Claspin degradation.
Increased radiosensitivity of MCF10A cells overexpressing
Aurora-A
Deficient HR causes sensitivity to ionizing radiation. Therefore,
we examined the effect of high level Aurora-A expression on the
radiosensitivity of normal human mammary epithelial cells
(MCF10A) using a clonogenic survival assay (Fig 6A). In this
assay, MCF10A cells were infected with lentiviral vectors
expressing either high levels of both Aurora-A and GFP (from a
bicistronic mRNA; Aurora-A) or GFP alone (empty vector;
Fig 6C). The ability of these cells to form colonies after
irradiation was assessed. As expected, we observed a dose-
dependent decrease of the colony formation. Moreover, the
overexpression of Aurora-A substantially aggravates the effect
of irradiation, when compared to cells expressing GFP alone. To
confirm these results, we performed a GFP competition assay in
which empty vector-, or Aurora-A-infected cells were mixed
with non-infected cells used as an internal control (Fig 6B). As in
the colony formation assay, Aurora-A overexpression sensitizes
MCF10A cells to irradiation in a dose-dependent manner. This
suggests that Aurora-A expression modulates radiosensitivity
and provided further evidence that high levels of Aurora-A
might interfere with HR. 2010 EMBO Molecular Medicine 135
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Figure 5. Aurora-A overexpression correlates with decreased CHK1 activity.
A. MCF10A cells infected with a lentiviral construct expressing Aurora-A
(Aurora-A) or the corresponding empty vector (empty vector) were treated
by 5-Gy X-ray, followed by 24 h recovery. Cell lysates were prepared and
immunoprecipitated CHK1 kinase activity was measured by in vitro kinase
assay using MBP as a substrate. Equal levels of total MBP and IgG heavy
chain were monitored by Coomassie blue staining.
B. Quantification of CHK1-induced MBP phosphorylation. Kinase assay sig-
nals from (A) were quantified. The average of two independent exper-
iments was plotted. Error bars indicate SEM.
C. The amount of Claspin, total CHK1, Serine 317-phosphorylated CHK1
(p-Ser317-CHK1), Serine 345-phosphorylated CHK1 (p-Ser345-CHK1),
total CHK2, threonine 68-phosphorylated CHK2 (p-T68-CHK2) and
Aurora-A were determined in the cell lysates used in (A) by
immunoblotting. Ezrin was used as loading control.
136Aurora-A overexpression confers sensitivity to PARP inhibition
PARP inhibition generates DNA lesions that are normally
repaired by HR, and accordingly cells with compromised HR are
highly sensitive to PARP inhibition (Ashworth, 2008). It has
been previously shown that the CAPAN1 pancreatic tumour cell
line, which carries the protein-truncating c.6174delT frameshift
mutation (Goggins et al, 1996), is highly sensitive to PARP
inhibitors such as KU0058948 (Edwards et al, 2008; McCabe
et al, 2005). We have previously generated a CAPAN1-derived 2010 EMBO Molecular MedicinePARP inhibitor-resistant cell line, PIR12, which carries a
functional BRCA2 gene and is thus HR competent (Edwards
et al, 2008). We used this model to explore the effect of high
level of Aurora-A expression on PARP inhibitor sensitivity.
Ectopic expression of Aurora-A sensitized the normally
HR-competent PIR12 cell line to the potent PARP inhibitor
KU0058948 (Farmer et al, 2005; Fig 6D, E). Conversely,
high level Aurora-A expression was unable to increase
PARP inhibitor sensitivity in the isogenic, HR deficient,
CAPAN1 cell line. Finally, to assess the in vivo selectivity of
PARP inhibition towards Aurora-A overexpressing tumours,
we performed xenograft studies in nude mice using
CAPAN1 (Fig 6F) and PIR12 (Fig 6G) cells expressing normal
or high levels of Aurora-A. Mice were treated with the
PARP inhibitor KU0058948. Similarly to our in vitro data
(Fig 6D), the CAPAN1 tumours were sensitive to the PARP
inhibitor, regardless of Aurora-A status (p< 0.001 and <0.05,
respectively). The PIR12 tumours, however, were resensitized
to PARP inhibition by overexpression of Aurora-A (p< 0.001).
Our data showing radiosensitization of Aurora-A overexpres-
sing cells combined with the finding that PARP inhibitor
sensitivity was increased by high Aurora-A expression, further
suggest that HR is suppressed and that these cells may be
sensitized to agents targeting deficiencies in this DNA repair
pathway.CONCLUSION
Here, we show that Aurora-A overexpressing cells have sup-
pressed HR. Our results suggest a signalling cascade emanating
from Aurora-A, where activated PLK1 represses CHK1 activity
through Claspin regulation, resulting in inhibition of RAD51
function and decreased HR (Fig 7). HR activity has been recently
reported to be repressed before and upon mitotic entry (Mao
et al, 2008b). This repression of HR has conceivably evolved to
prevent annealing of DNA between sister chromatids as they are
scheduled to segregate into daughter cells. Interestingly, the
repression of HR that occurs upon mitotic entry parallels the
normal expression and activation pattern of Aurora-A. Repres-
sion of HR upon entry to mitosis might be part of the normal
function of Aurora-A.EMBO Mol Med 2, 130–142 www.embomolmed.org
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Figure 6. Aurora-A overexpression enhances cell
sensitivity to irradiation and to PARP inhibition.
A. MCF10A cells were infected with a lentivirus
construct driving the expression of GFP (empty
vector) or both GFP and Aurora-A (Aurora-A),
and then exposed to 0-, 2-, 5- or 10-Gy X-ray.
After a 7 days recovery, cells were re-plated at
the indicated dilutions, left to grow for 7 days
and stained with crystal violet.
B. MCF10A cells were infected with a lentivirus
construct driving the expression of GFP (empty
vector) or both GFP and Aurora-A (Aurora-A)
and mixed in equal proportion with non-
infected cells to provide an internal control.
The mixed cells were exposed to 0-, 2-, 5- or
10-Gy X-Ray, as indicated. GFP expression was
determined by flow cytometry at the indicated
time and the proportion of infected, GFP-
positive cells in the live cells population was
plotted. Error bars represent SEM.
C. Cell lysates were prepared from infected
MCF10A cells used in (B) and the expression of
Aurora-A was determined by immunoblotting.
Ezrin was used as loading control.
D. CAPAN1 and PIR12 cells were infected with a
lentivirus construct driving the expression of
GFP (empty vector) or both GFP and Aurora-A
(Aurora-A), and exposed to the PARP inhibitor
KU00589482 or to vehicle for sixty days. Cell
viability was measured as described in
Material and Methods. The mean and SD of a
representative experiment with internal
triplicate are shown.
E. Cell lysates were prepared from CAPAN-1 and
PIR12 cells used in (D). The expression of
Aurora-A and GFP were determined by
immunoblotting. Ezrin was used as loading
control.
F, G. CAPAN1 and CAPAN1 cells overexpressing
Aurora-A (F) and PIR12 and PIR12
overexpressing Aurora-A (G) were injected into
the lateral flanks of athymic nude mice. The
results are expressed as fold increase in
tumour volume, SEM. p-values were
calculated by two-way ANOVA.
www.embomolmed.org EMBO Mol Med 2, 130–142  2010 EMBO Molecular Medicine 137
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138We did not observe persistence of g-H2AX signal in cells
overexpressing Aurora-A, suggesting that the repair might be
fulfilled by an alternative error-prone mechanism. A series of
reports have demonstrated that in the absence of functional HR,
error-prone repair mechanisms predominate (Moynahan et al,
2001; Tutt et al, 2001). Amongst the possible alternative
mechanisms to HR, NHEJ is a good candidate as the repaired
DSBs in HR deficient cells are characterized by deletions flanked
by short tandem repeats (Edwards et al, 2008) which is
reminiscent of the repair performed by NHEJ mechanism. The
use of NHEJ, which is a faster process compared to HR, is also
suggested by the shorter cell cycle arrest observed in Aurora-A
overexpressing cells (Fig 2A, B; Mao et al, 2008a).
Our results suggest that overexpression of Aurora-A results in
a repression of the error-free HR pathway, presumably
favouring a lower-fidelity process, such as NHEJ. This might
consequently increase genomic instability and account, at least
in part, for the oncogenic activity of Aurora-A. Finally, several
small molecule inhibitors of PARP have shown therapeutic
efficacy against tumours deficient in HR in pre- and early clinical
studies (Bryant et al, 2005; Farmer et al, 2005; Fong, 2009). Our
results suggest that Aurora-A overexpression decreases the
repair of DSB by HR pathways and confers sensitivity to
PARP inhibition. This latter observation may have importantFigure 7. Model for the regulation of the DNA damage response by Aurora-A
A. During the S and G2 phases of the cell cycle, HR is the preferred pathway to r
recombinase, while stalling the cell cycle by keeping CDK1 inactive. CDK1 inact
phosphatases and Wee1 kinase by CHK1.
B. High levels of Aurora-A result in constitutive activation of the PLK1 kinase. Clas
the G2 checkpoint recovery phase. The inactivation of CHK1 that ensues wea
Consequently, DNA is repaired by the constitutively operative NHEJ pathway. Th
after irradiation might be a result of both the activation of a faster DNA repa
 2010 EMBO Molecular Medicineimplications for the development of cancer therapeutics aimed
at targeting tumour cells with Aurora-A overexpression. More-
over, previous studies have reported a lack of correlation
between the sensitivity of cells treated with Aurora kinase
inhibitors and Aurora-A levels (Chan et al, 2007; Soncini et al,
2006) suggesting that methods other than targeting Aurora-A are
required. This raises the possibility of extending the therapeutic
utility of PARP inhibition to tumours with high levels of Aurora-
A expression.MATERIALS AND METHODS
Inhibitors
Aurora-B inhibitor ZM447439 (Ditchfield et al, 2003) and PLK1
inhibitor BI2536 (Steegmaier et al, 2007) were obtained from Tocris
Bioscience and AxonMedchem, respectively. Aurora-A inhibitor
MLN8054 (Manfredi et al, 2007) was synthesized in-house. The PARP
inhibitor KU0058948 was provided by KuDOS Pharmaceuticals.
Cell culture and transfection
HEK 293 and the packaging line 293T were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco) supplemented with 10%
foetal calf serum (FCS), 2.4mM L-glutamine, 100U/ml penicillin and.
epair DSBs. Activated CHK1 stimulates repair by phosphorylating the RAD51
ivation is mediated by a number of pathways, including inactivation of CDC25
pin is degraded upon phosphorylation by PLK1, an event normally restricted to
kens the response of HR protein, such as RAD51 accumulation to the DSBs.
e shortening of the cell cycle arrest observed in Aurora-A overexpressing cells
ir process, such as the NHEJ pathway and the stimulation of CDK1.
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The paper explained
PROBLEM:
The Aurora-A gene is frequently upregulated in a variety of
cancers, including breast and colon cancer. The clinical
application of inhibitors of Aurora-A kinase activity is now being
evaluated in clinical trials. However, there is a need for a better
understanding of the oncogenic properties of Aurora-A to identify
the relevant patient population for treatment.
RESULTS:
We demonstrate that deregulation of Aurora-A in normal and
cancer cell lines affects DNA damage repair. Aurora-A represses
the HR repair pathway and confers increased cellular sensitivity
to PARP inhibitors (known to target cancer cells with deficient
DNA repair pathways) in vitro and in vivo.
IMPACT:
The data shed light on the molecular mechanisms underlying
Aurora-A tumorigenic properties and we propose using PARP
inhibitors as a new therapeutic approach to target tumour cells
with upregulated Aurora-A.100mg/ml streptomycin. MCF10A cells were grown in DMEM/F12
(1:1) medium (Gibco) supplemented with 5% horse serum, epidermal
growth factor (20 ng/ml) (Peprotech), hydroxycortisone (0.5mg/ml),
cholera toxin (100 ng/ml), insulin (10mg/ml) (Sigma–Aldrich), peni-
cillin (60mg/ml) and streptomycin (100mg/ml). CAPAN1 and PIR12
cells were grown in DMEM (Gibco) supplemented with 20% FCS,
2.4mM L-glutamine, 100U/ml penicillin and 100mg/ml streptomycin.
ES cells were grown on mitomycin-inactivated mouse embryonic
fibroblasts (MEF) as feeder cells, or on a gelatin-coated substrate in
DMEM (Sigma) supplemented with 15% FCS, 2mM L-glutamine
(Sigma), MEM-non-essential amino acids (Gibco), 50 mM 2-
mercaptoethanol (Gibco) and 100 U/ml (when grown on feeder MEFs)
or 200U/ml (when grown on gelatin-coated substrate) LIF (Esgro,
Chemical International).
Transfection of 293T packaging cells, 293 and ES cells was carried
out using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s protocol.
Plasmids and lentiviruses
A human myc-tagged Aurora-A cDNA was PCR amplified using the
following primers containing a PmeI restriction site: AurA F 50-
GTTTAAACATGGAGCAGAAGCTG-3 0 , AurA R 5 0-GTTTAAACCTAA-
GACTGTTTGCT-30 and pCMV-myc-Aurora-A as a template. The
amplification product was inserted into PCR2.1 (Invitrogen). The cDNA
was released by PmeI digestion before insertion into PmeI linearized
pWPI lentiviral expression plasmid (addgene). Mutations in Aurora-A
cDNA were performed by site directed mutagenesis. The human
Gadd45a cDNA was a kind gift from Richard Bayliss. The cDNA was
released from the pET30 plasmid by digestion with EcoRI and NcoI,
treated with Klenow DNA polymerase to generate blunt ends and
inserted into the PmeI linearized pWPI.
The lentivirus production in 293T packaging cells was performed
following the guidelines provided by Didier Trono’s laboratory
(available online http://tronolab.epfl.ch/). Briefly, 293T cells were co-
transfected as described above with the pWPI expression plasmids, the
packaging plasmid psPAX2 and the envelope vector pMD2.G.
Transfection medium was changed after 16 h, and the lentivirus-
containing medium was subsequently harvested every 24 h forwww.embomolmed.org EMBO Mol Med 2, 130–1423 days and frozen at –808C. Infectivity of the viral solution was
titrated on 293T cells. MCF10A, CAPAN1, PIR12 and HEK293 were
infected by adding viral particles to the growing medium for at least
24 h.
Immunofluorescence
Cells grown on a glass coverslip were fixed in PBS–4% paraformaldehyde
for 1h, permeabilized in PBS–0.5% Triton X-100 for 15min, blocked in
PBS–2%FCS–1%BSA, before incubation with rabbit-anti-RAD51 (Santa
Cruz) and mouse-anti-g-H2AX (Upstate) antibodies. Secondary
antibodies were Alexa Fluor1 555-conjugated goat anti-rabbit IgG
(Hþ L) and Alexa Fluor1 633-conjugated goat anti-mouse IgG (Hþ L)
(Invitrogen). DNA was conterstained with 40 ,6-diamidino-2-phenylindole
(DAPI). Image acquisition was performed on a Leica SP2 confocal
scanning microscope (Leica Microsystems, Milton Keynes, Bucks, UK).
Flow cytometry
Flow cytometry data acquisition was performed on a BD LSR II flow
cytometer (BD). Analysis was carried out using the FacsDiva software
(BD). For all flow cytometry analysis, live cells were gated based on a
FSC-A versus SSC-A dot plot. GFP was detected using the FITC-A
channel. DNA profiling was performed by propidium iodide (PI)
staining of cold ethanol fixed-cells after RNAse treatment (ES cells)
using the PE-Cy5 channel, or by live staining with Hoechst 33342
(Pacific blue channel). In both cases, single cells were selected for
analysis based on SSC-W versus SSC-A and PE-Cy5-W versus PE-Cy5-A
(PI staining) or Pacific blue-W versus Pacific blue-A (Hoechst 33342
staining) plot gating.
Immunoblotting, immunoprecipitation and kinase assay
Proteins were extracted in lysis buffer (50mM HEPES pH 7.4, 250mM
NaCl, 0.5% Igepal CA-630 (Sigma), protease inhibitor (Complete,
Roche), 0.1mM Na3VO4, 1mM NaF, 10mM b-glycerophosphate). The
following antibodies were used for immunoblotting: Rabbit anti-
Aurora-A, anti-p-Ser317-CHK1, anti-p-Ser345-CHK1 and anti-p-
Thr68-CHK2 (Cell Signalling), rabbit anti-Claspin (Abcam), mouse
anti-Aurora-A and mouse anti-GFP (clone JL-8) (BD Bioscience), goat
anti-CHK2, mouse anti-CHK1 (Santa Cruz), mouse anti-p-T210-PLK1 2010 EMBO Molecular Medicine 139
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140(BD Pharmingen) and mouse anti-PLK1 (Upstate). The anti-Ezrin
antibody used for loading control was a kind gift from Prof. Clare
Isacke.
For immunoprecipitation, 500mg of protein was diluted 1:10 in
binding buffer [PBS supplemented with protease inhibitor (Complete,
Roche), 0.1mM Na3VO4, 1mM NaF, 10mM b-glycerophosphate] and
incubated with 2mg of mouse anti-CHK1 antibody (Santa Cruz)
overnight at 48C. Immunocomplexes were pulled-down by addition of
Protein A-AgarosePlus (Santa Cruz) and washed three times in binding
buffer, resuspended in 1 kinase assay buffer (50mM Tris pH 7.5,
10mM NaCl, 2.5mM MgCl2, 1mM DTT). The kinase reaction was
performed in the presence of 0.5mg/ml MBP, 10mM cold ATP, 2mCi
g-33P-ATP (3000 Ci/mmol, 10mCi/ml, PerkinElmer), at 258C for
30min. Proteins were then resolved in SDS–PAGE before autoradio-
graphy. Band density was measured using the ImageJ software. The gel
was subsequently rehydrated and Coomassie stained (SimplyBlue
SafeStain, Invitrogen).
Homologous recombination reporter assay
293 cells bearing the stably integrated DNA repair reporter construct
(see Fig 3; Tutt et al, 2001) were infected with lentiviruses expressing
GFP alone or GFP along with Aurora-A (wild type or mutants) or
Gadd45a. Cells were subsequently co-transfected with a plasmid
expressing an NLS-tagged I-SceI restriction enzyme and a DsRed
expressing vector. After 24 h, the transfection efficiency was assessed
by flow cytometry quantification of DsRed positive cells. For colony
formation assay, cells were plated in six-well plates in the presence of
5mg/ml of blasticidin (Invitrogen; 1.2106 cells) or without
(3105 cells) antibiotic. After 21 days, cells were fixed and stained
with crystal violet. Colonies were counted in a ColCount (Oxford
Optronics). For the GFP competition assay, GFP positive cells were
quantified by flow cytometry at various time during the selection
process.
PARP inhibitor sensitivity assay
Exponentially growing cells were seeded in 24-well plates and
exposed continuously to the PARP inhibitor KU0058948 (gift from
KuDOS/AstraZeneca) at concentrations ranging from 10–9 to 10–5M,
or DMSO. Medium and inhibitor were replaced every 4 days. PARP
inhibitor- or DMSO-treated cells were split equally when appropriate.
After 60 days the survival of KU0058948 versus DMSO-treated cells
was measured using a luminescent cell viability assay (CellTiter-Glo,
Promega).
Xenografts
CAPAN1 and PIR12 cells (4106) infected with empty lentiviral
vector (empty vector) or a vector expressing Aurora-A (Aurora-A) were
mixed 1:1 in matrigel (BD Biosciences) and then injected subcuta-
neously into the lateral flank of 6- to 8-week-old female athymic
nude mice (12 animals per cohort, 24 in total). The mice were
allowed to recover for 2 days and then treated with KU0058948 or
vehicle alone. PARP inhibitor (or vehicle) was administered by
intraperitoneal injection at a dose of 15mg/kg in 10% 2-hydro-
xypropyl-b-cyclodextrin (HBC; Farmer et al, 2005) for five consecutive
days followed by 2 days of no treatment after which the
same treatment cycle was continued until the end of the study.
Tumour volumes were measured every 2–4 days from the initiation of 2010 EMBO Molecular Medicinetumour growth. Tumours were measured every 2–4 days after the
initiation of drug dosing. The results are expressed as fold increase in
tumour volume, SEM. p-values were calculated by two-way
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